Xbrane's (ST:XBRANE) first sales in 2017 will be of Spherotide: the first generic formulation of the prostate cancer therapy triptorelin (cancer sales about $380m). A SEK7m order is ready for shipment to Iran, once authorised. A Chinese deal worth SEK17m upfront, $8m total, may be signed in Q117. European partnering and launches are possible from 2019 after clinical trials. Xbrane (or a partner) may sell Xlucane, its low-cost biosimilar of Lucentis (2015 sales $3.6bn), in the US after 2021 and from 2022 in Europe.
Prostate cancer: First triptorelin generic to market
Triptorelin, sold as various brands including Decapeptyl (Ipsen; 2015 sales: €334m), is used to treat advanced prostate cancer, endometriosis and uterine fibroids. Sales in 2015 for these indications were $380m. Triptorelin is one of a well-known class that suppress GnRH receptors. The leaders are goserelin (Zoladex, AstraZeneca; 2015 sales: $816m) and leuprolide (Lupron, AbbVie; $826m). Initial Spherotide sales are planned in 2017 with a SEK7m order to Iran. An agreed, but not signed, Chinese $8m deal should yield SEK17m cash in Q117 with sales perhaps from 2021/22. EU marketing is expected from 2019 via a partner.
To read the entire report Please click on the pdf File Below